BiotechTube
Nexstim

Nexstim

Helsinki, Finland· Est.
nexstim.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $20M

Overview

Nexstim is a commercial-stage medical device company with a unique focus on navigated Transcranial Magnetic Stimulation (nTMS). Its proprietary SmartFocus® technology platform integrates patient-specific MRI data with a multi-sphere head model to visualize and navigate the induced electric field (E-field) in the brain in real-time, enabling unprecedented targeting accuracy. The company's NBS systems are used for pre-surgical mapping in neurosurgery and for therapeutic treatment of conditions like depression and obsessive-compulsive disorder (OCD). As a publicly traded company, Nexstim is expanding its commercial footprint and regulatory clearances for its latest NBS System 6.

DepressionObsessive Compulsive Disorder (OCD)NeurosurgeryEpilepsyPost-Operative Rehabilitation

Technology Platform

SmartFocus® Navigated Transcranial Magnetic Stimulation (nTMS) with E-field visualization. Uses a proprietary multi-sphere head model (over 40,000 spheres) derived from patient MRI to calculate and navigate the precise location, orientation, and magnitude of the induced electric field in the brain in real-time.

Funding History

2
Total raised:$20M
IPO$8M
Series B$12M

Opportunities

The recent FDA clearance for OCD treatment opens a substantial new market alongside its established depression business.
The growing adoption of nTMS as a standard of care in neurosurgery provides a stable diagnostic revenue stream.
Increasing global focus on mental health and non-pharmacological treatments creates favorable tailwinds for therapeutic TMS adoption.

Risk Factors

Commercial success depends on securing and expanding insurance reimbursement for therapeutic procedures, which is often a slow and challenging process.
The company faces competition from larger, well-capitalized TMS manufacturers and alternative neuromodulation technologies.
As a relatively small public company, it carries execution risk in scaling its global sales and marketing efforts simultaneously.

Competitive Landscape

Nexstim competes in the broader TMS market against companies like MagVenture (a major diagnostic and therapeutic TMS supplier) and BrainsWay (deep TMS for depression and OCD). Its key differentiator is its proprietary, real-time E-field navigation for precision targeting, a feature not offered by standard TMS systems. It also competes in the surgical planning space against other brain mapping technologies.

More companies in Neuroscience & CNS →More companies in Finland →